All Experts


Meet the Expert: Wayne J. G. Hellstrom, MD, FACS
Professor, Urology
Tulane University School of Medicine
New Orleans, Louisiana, USA

Wayne John G. Hellstrom, MD, FACS, is Professor of Urology at Tulane University School of Medicine in New Orleans, Louisiana. He is Chief of the Section of Male Infertility and Sexual Dysfunction at Tulane University Health Sciences Center and Chief of the Section of Urology at Charity Hospital of New Orleans. He is also on staff at the Veterans Administration Medical Center, New Orleans.

Dr. Hellstrom received his medical degree from McGill University Medical School in Montreal, Canada, and he completed an internship and residency in general surgery in the McGill University Hospital system. Additional postdoctoral training included a residency in urology at the University of California, San Francisco, and a 2-year American Urological Association (AUA) Scholar funded fellowship in andrology from the University of California, Davis.

Among Dr. Hellstrom's key research interests are premature ejaculation, male infertility, surgery for erectile dysfunction (ED), Peyronie's disease, gene transfer techniques for ED, and the development of new pharmacologic vasoactive erection drugs in various animal models. He has served as principal investigator for clinical trials evaluating the use of transurethral alprostadil; the oral phosphodiesterase type 5 inhibitors–tadalafil, vardenafil, and sildenafil–for the treatment of ED; premature ejaculation drugs; and a number of other pharmacologic applications for ED prevention and treatment.

A prolific writer, Dr. Hellstrom has published more than 300 peer-reviewed papers, more than 150 book chapters, and numerous reviews. Notably, he is the author of The Handbook of Sexual Dysfunction and editor of the textbook Male Infertility and Sexual Dysfunction. His articles have been published in the New England Journal of Medicine, Urology, Journal of Urology, Journal of Andrology, Fertility and Sterility, Urological Research, British Journal of Urology, International Journal of Andrology, and Proceedings of the National Academy of Sciences. Dr. Hellstrom is Associate Editor of Journal of Sexual Medicine and the International Journal of Andrology and is a reviewer for many other journals. Renowned for his expertise in male sexual health, Dr. Hellstrom has been an invited speaker in the United States and abroad.

A Fellow of the American College of Surgeons, Dr. Hellstrom has received many honors throughout his distinguished career in urologic medicine. Among his awards are the Young Andrologist Award granted by the American Society of Andrology, the Hume Award for Excellence in Urological Research, and the AUA First Prize for Clinical Research. His professional memberships include the American Urological Association, American Society of Andrology, American Fertility Society/American Society for Reproductive Medicine, Société Internationale d'Urologie, and the International Society for Sexual Medicine (ISSM). Sexual Medicine Society of North America (SMNA) and Society for Urologic Prosthesis (SUPs).

Editorships:

• International Journal of Andrology, Associate Editor
• Asian Journal of Andrology, Editorial Board Member
• Issues in Sexual Medicine, Section Editor
• Journal of Urology, Specialty Society Editor (SMSNA)
• Current Sexual Health Reports, Section Editor
• Biology of Reproduction (Reviewer)
• Journal of Clinical Investigation (Reviewer)
• Urology (Reviewer)
• Journal of Urology (Reviewer)
• Journal of Andrology (Reviewer)

Research Interests:

• Male infertility
• Erectile dysfunction
• Sperm stimulation protocols for improving motion parameters of sperm
• Development of new pharmacological vasoactive erection drugs in animal models
• Peyronie’s disease—both basic research and clinical studies
• Penile rehabilitation post-prostatectomy
• Gene therapy in the treatment of erectile dysfunction

Professional Memberships:

• American Fertility Society/American Society for Reproductive Medicine (1988 - 2005)
• American Medical Association (1988-1994)
• American Society of Andrology
• American Urological Association
• Fellow of the American College of Surgeons
• International Society for Sexual Medicine (ISSM)
• Sexual Medicine Society of North America (SMSNA)
• Society of Urologic Prosthetic Surgery (SUPS)
• Louisiana State Medical Society
• Medscape Urology, Board member
• Northern California Association of Urologists (1983-1988)
• Orleans Parish Medical Society
• Societe Internationale d'Urologie
• Society of Genitourinary Reconstructive Surgeons (GURS)
• Society of Male Reproduction and Urology
• Society of University Urologists, Inc.
• Southeastern Section of the AUA
• Southern Medical Association

Selected Publications:

• Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation


• Effects of alfuzosin and tamsulosin on sperm parameters in healthy men: results of a short-term, randomized, double-blind, placebo-controlled, crossover study


• Medical management of Peyronie's disease


• Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment


• A critical appraisal of erectile function in animal models of diabetes mellitus


• Sex and the infertile male


• Emerging treatments for premature ejaculation: focus on dapoxetine


• 5-alpha reductase inhibitors and erectile dysfunction: the connection


• A review of current progress in gene and stem cell therapy for erectile dysfunction


• The pharmacological treatment of premature ejaculation


• Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations


• Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls


• The chronology of depression and distress in men with Peyronie's disease


• Clinical applications of centrally acting agents in male sexual dysfunction


• An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation


• Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress


• An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study


• Distinguishing premature ejaculation from other sexual function disorders


• Premature ejaculation: current and future treatments


• Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction


• Tramadol HCL has promise in on-demand use to treat premature ejaculation


• The effect of vascular risk factors on penile vascular status in men with erectile dysfunction


• Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum


• Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors


• Peripheral mechanisms of erectile dysfunction in a rat model of chronic cocaine use


• Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation


• Diabetes mellitus is associated with severe Peyronie's disease


• Pharmacological Management of Peyronie's Disease


• Gene therapy for erectile dysfunction: fact or fiction?


• Management of sildenafil treatment failures


• Treatment of premature ejaculation: new drugs and treatment strategies


• Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers


• Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials


• Current and future pharmacotherapies of premature ejaculation


• Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction


• Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease


• Synchronous prosthetic implantation through a transscrotal incision: an outcome analysis


• Update on erectile dysfunction in prostate cancer patients


• Semen and sperm reference ranges for men 45 years of age and older


• Current concepts in ejaculatory dysfunction


• Gene and stem cell therapy for erectile dysfunction


• Central nervous system agents in the treatment of erectile dysfunction


• Vardenafil in patients with erectile dysfunction: achieving treatment optimization


• The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease


• The relationship between the type of penile abnormality and penile vascular status in patients with peyronie's disease


• Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis


• Endothelial nitric oxide synthase gene therapy for erectile dysfunction


• The impact of vascular risk factors on erectile function


• Vardenafil provides reliable efficacy over time in men with erectile dysfunction


• Critical analysis of surgery for Peyronie's disease


• The hydrophilic-coated inflatable penile prosthesis: 1-year experience


• Stratification of penile vascular pathologies in patients with Peyronie's disease and in men with erectile dysfunction according to age: a comparative study


• Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction


• Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease


• Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction


• Vardenafil: a new approach to the treatment of erectile dysfunction


• Surgical approaches for advanced Peyronie's disease patients


• History, epidemiology, and clinical presentation of Peyronie's disease


• Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones


• Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease


• Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial


• Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease


• Intralesional interferon-alpha-2b for the treatment of Peyronie's disease


• Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternatives


• Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism


• Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease


• Long-term follow-up on use of pericardial graft in the surgical management of Peyronie's disease


• Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction


• Peyronie's disease: advances in basic science and pathophysiology


• Pharmacotherapy for erectile dysfunction


• The effect of sildenafil on human sperm motion and function from normal and infertile men


• Peyronie's disease: etiology, medical, and surgical therapy


• Application of pericardial graft in the surgical management of Peyronie's disease


• Nitric oxide-mediated erectile effects of galantide but not galanin in vivo